Skip to content
Clinical Trials – home

Universitetska Mnogoprofilna bolnica za aktivno lechenie Deva Maria EOOD

Verified siteinfo

Bulgaria Vazrazhdane Str. 13, 8000 Burgas, Bulgaria

  • 4 trials recruiting
  • Acute myocardial infarction · Abdominal infection · Arteriosclerosis
  • Adults and children

About Specializations

Universitetska Mnogoprofilna bolnica za aktivno lechenie Deva Maria EOOD in Burgas, Bulgaria specialises in clinical trials of conditions such as Acute myocardial infarction, Abdominal infection, Arteriosclerosis, Atrial fibrillation, and other specialisations. This site conducts important research.

Main research areas of the site

Bacterial Infections and Mycoses

At Universitetska Mnogoprofilna bolnica za aktivno lechenie Deva Maria EOOD in Burgas, clinical research in bacterial infections focuses on serious hospital-treated illnesses in vulnerable patients, especially neonates and infants. The studies are designed to better understand treatment behavior and support improved care for severe infections caused by gram-negative bacteria.

  • Suspected or confirmed gram-negative infections requiring intravenous antibiotic treatment
  • Complicated urinary tract infection and complicated intra-abdominal infection
  • Blood stream infection, sepsis, and hospital-acquired pneumonia or ventilator-associated pneumonia

This research is mainly aimed at evaluating a new antibacterial therapy for safety, tolerability, and how the body processes treatment in young hospitalized patients.

Cardiovascular Diseases

The Clinic of Cardiology at this hospital is also involved in studies on cardiovascular disease, with a focus on patients who have recently experienced a heart attack or who live with hypertension and elevated cardiovascular risk. These trials explore ways to lower the chance of future heart and vascular events.

  • Type 1 AMI, including STEMI and NSTEMI
  • Established cardiovascular disease and high cardiovascular risk
  • Hypertension not adequately controlled

The main goal is to test new approaches that may reduce major adverse cardiovascular events, improve prevention, and support better long-term outcomes after acute or chronic heart disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Vazrazhdane Str. 138000 BurgasBulgaria
Recruiting now
4 trials
Conditions studied
12
Partner status
Verified site

More sites in BurgasBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

7 clinical trials

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:BulgariaBulgaria
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Abdominal infection+5

Not yet recruiting

Study on Aztreonam, Avibactam, and Metronidazole for Treating Infections in Neonates and Infants Under 9 Months with Gram-Negative Bacterial Infections

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Avibactam Sodium
  • Sponsor:Pfizer Inc.

Arteriosclerosis

Not recruiting

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Obicetrapib
  • Sponsor:NewAmsterdam Pharma B.V.

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.